HOLX Stock: Hologic, Inc. Stock Price, Analysis & Insights
Get live holx stock price $74.06, comprehensive Hologic, Inc. stock analysis, charts, news, and expert forecast. Real-time holx stock data and investment insights.
Loading chart...
Company Overview
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Company Information
- CEO
- Stephen P. MacMillan
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 7063
Contact Information
- Website
- https://www.hologic.com
- Address
- 250 Campus Drive
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 30.7)
✓ Lower volatility stock (Beta: 0.63) may provide portfolio stability
Business Model & Strategy
Hologic, Inc. operates in the Medical - Instruments & Supplies industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Stephen P. MacMillan, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Medical - Instruments & Supplies model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Hologic, Inc. competes in the Medical - Instruments & Supplies within the broader Healthcare. With 16.5 billion in market capitalization, the company is positioned as a established player in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Hologic, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Hologic, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Hologic, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Hologic, Inc.
- ⚠Investors should consider how Hologic, Inc. fits within their overall portfolio allocation
- ⚠Premium valuation (P/E: 30.7) requires strong growth to justify
Market Cap
16.47B
P/E Ratio
30.73
Beta
0.63
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 16.47B market capitalization
- Trading Volume: 2.82M shares traded today
- Price Range: 52-week range of $51.90 - $81.14
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Hologic, Inc.
Hologic, Inc. (HOLX) operates in the Medical - Instruments & Supplies industry within the Healthcare sector. With a current market capitalization of 16.47B, the company represents a significant player in its market. The stock is currently trading at $74.06 with a positivedaily change of 0.20%.
The company's 7063 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 30.73, beta of 0.63, and 52-week price range from $51.90 to $81.14when evaluating investment opportunities.
Why Invest in Hologic, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Stephen P. MacMillan
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.